Blood Plasma Derivatives Market 2019 Analysis - Research Covers Top 10 Players as Grifols, SK Plasma, Fusion Healthcare, Baxter International Inc., CSL Limited

Newest Report with Tilted as “Blood Plasma Derivatives Market” is added on MarketReseacrhFuture.com. Covered all the Regions and Segments and Sub Segments with Top Manufacturers. Outlet till 2023.

Global Blood Plasma Derivatives Market - Competitive Analysis

Grigols (Spain), Baxter International Inc. (US), Octapharma AG (Switzerland), CSL Limited (Australia), Kedrion S.p.A (Italy), Bain Capital, LLC (US), Biotest AG (Germany), Fusion Healthcare (India), SK Plasma Co., Ltd. (South Korea) are some of the prominent players at the forefront of competition in the blood plasma derivatives market and are profiled in MRFR Analysis.

Global Blood Plasma Derivatives Market - Industry News        

On July 27, 2017, Baxter International Inc. completed the acquisition of Claris Injectables Limited for approximately USD 625 million. The main motive of acquisition is the expansion of generic pharmaceuticals.

On June 06, 2017, ADMA Biologics, Inc., a biopharmaceutical company, has acquired therapy business unit of Biotest Pharmaceuticals. As a result of this, ADMA acquired two FDA approved products i.e. Nabi-HB™, and and BIVIGAM™.

Request Sample Report at https://www.marketresearchfuture.com/sample_request/1325

Global Blood Plasma Derivatives Market - Overview

The Market is forecasted to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period 2018 – 2023.

Plasma is a fluid part of the blood that contains blood cells, and protein responsible for blood clotting. Plasma derivatives are obtained from specific plasma proteins by the process of fractionation. The derivatives are then solvent detergent-treated or heat-treated to kill certain viruses. The most common plasma derivative includes factor IX concentrate, factor VIII concentrate, anti-inhibitor coagulation complex (AICC), anti-thrombin III concentrate, immune globulins, Alpha 1-Proteinase inhibitor concentrate, albumin, and anti-thrombin III concentrate.

Blood plasma derivative widely used clinically to treat various conditions such as hemophilia A, hemophilia B, HIV, hepatitis B, hepatitis C, thrombocytosis, and others. 

Other factors such as, rising incidence of hemophilia, huge funding for research & development, technological advancements, and rising approval from regulatory bodies are also fuelling the market growth. According to the Centers for Disease Control and Prevention, it is found that Hemophilia A affects 1 in 5,000 male births i.e. around 400 babies are born with hemophilia A every year.

Despite these drivers, stringent reimbursement policies, safety concerns, and high cost of treatment is expected to decline the blood plasma derivatives market growth.

The global blood plasma derivatives market is currently dominated by few players.

Grigols is one of them by holding a strong share in the market. The company’s stronghold is largely attributed to its innovative and sustainable products. Grigols aoperates in three major divisions i.e. Bioscience, Diagnostic and Hospital. On November 17, 2017 Grigols received FDA approval for a new genetic test used to detect alpha-1 antitrypsin deficiency. On November 11, 2013, Grifols acquired blood transfusion testing unit of Novartis AG for USD 1.68 billion. In the year 2016, Grifols has also acquired NAT (Nucleic Acid Testing) donor screening unit of Hologic for USD 1,850 million.

Browse Complete Premium Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/blood-plasma-derivatives-market-1325

Baxter is also one of the leading player in blood plasma derivatives market. Baxter International Inc., the US based biopharmaceutical company, operates in two major segments, i.e. Hospital Products and Renal. Baxter’s product Bebulin (Factor IX Complex) is specifically used for the prevention, of hemorrhagic episodes in case of hemophilia B. Bebulin may carry a risk of transmitting infectious agents, such as viruses and, Creutzfeldt‐Jakob disease (CJD) agent.

TOC of Blood Plasma Derivatives Market Research Report - Global Forecast to 2023

1 Report Prologue

2 Market Introduction

3 Research Methodology

4 Market Dynamics

5 Market Factor Analysis

6 Global Blood Plasma Derivatives Market by Type

7 Global Blood Plasma Derivatives Market by Application

8 Global Blood Plasma Derivatives Market by End Users

9 Global Blood Plasma Derivatives Market by Region

10 Competitive Landscape

11 Company Profile

Get Prime Discount at https://www.marketresearchfuture.com/check-discount/1325

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.